# Seer Files Patent Infringement Lawsuit Against Nanomics
Canonical URL: https://biopharmsignal.com/news/SEER/seer-files-patent-infringement-lawsuit-against-nanomics
Ticker: SEER
Company: Seer, Inc
Source: Seer, Inc
Published: 2026-05-13 11:01 EST
Original Source URL: https://investor.seer.bio
## Summary

Seer defends its pioneering Proteograph ® Product Suite intellectual property (IP) REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a patent infringement suit

## Article Body
Seer defends its pioneering Proteograph ® Product Suite intellectual property (IP) REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a patent infringement suit
## Recent Company News
- 2026-06-03 22:00 EST — [Seer Files Definitive Proxy Materials and Mails Letter to Stockholders](https://biopharmsignal.com/news/SEER/seer-files-definitive-proxy-materials-and-mails-letter-to-stockholders) — Source: Seer, Inc
- 2026-05-29 11:00 EST — [Seer Files ITC Complaint Against Nanomics](https://biopharmsignal.com/news/SEER/seer-files-itc-complaint-against-nanomics) — Source: Seer, Inc
- 2026-05-26 20:05 EST — [Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026](https://biopharmsignal.com/news/SEER/seer-to-showcase-ai-driven-multi-cancer-screening-approach-and-next-generation-proteomics-capabilities-at-asms-2026) — Source: Seer, Inc
- 2026-05-21 20:39 EST — [Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group](https://biopharmsignal.com/news/SEER/seer-board-of-directors-unanimously-rejects-further-revised-unsolicited-proposal-from-radoff-jec-group) — Source: Seer, Inc
- 2026-05-13 20:05 EST — [Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook](https://biopharmsignal.com/news/SEER/seer-reports-first-quarter-2026-financial-results-and-reaffirms-full-year-2026-outlook) — Source: Seer, Inc
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)